[Dyslipidemia and schizophrenia].
There is some evidence that the treatment with new ("atypical") neuroleptics is associated with a higher frequency of hyperlipidemia. In this study the serum lipid levels of patients with chronic schizophrenia were investigated. The serum lipid levels of 177 consecutively admitted schizophrenic patients treated at least 5 years were evaluated. No gender differences of lipid concentrations could be detected. A considerable rate of the patients (35.6 %) showed elevated triglycerides (> 150 mg/dl) or elevated cholesterol levels (> 200 mg/dl; 43.9 %). The rate of patients with elevated cholesterol or triglyceride concentrations is associated with the duration of treatment. The comparison of different groups of neuroleptics yielded at best a trend to higher triglyceride levels in the patients treated with dibenzodiazepines compared to those receiving only classical neuroleptics. The triglyceride concentrations correlated with the body mass index (rho = 0.25, p < 0.01). This study revealed evidence for an association of the rate of patients with elevated lipid levels and duration of neuroleptic treatment in schizophrenia patients.